Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Low-dose Bevacizumab in Relapsed GBM
NCT05502991Phase 2Not yet recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in glioblastoma (GBM), sponsored by Henan Provincial People's Hospital. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05502991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05502991.